Most studies dedicated to achieving a better understanding of mechanisms underlying tumor progression and optimizing immunotherapeutic gains have focused on antagonizing Foxp3+CD4+ Tregs (4, 5). This evidence concerns the gene FOXP3 and neoplasm.